X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
PLN-74809 (bexotegrast) is an oral, small molecule, dual-selective inhibitor of αvβ6 and αvβ1 integrins, which is being evaluated for the treatment of Idiopathic Pulmonary Fibrosis.
Lead Product(s): Bexotegrast
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: PLN-74809
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 12, 2024
Details:
PLN-74809 (bexotegrast) is an oral, small molecule, dual-selective inhibitor of the αvβ6 and αvβ1 integrins. It is being evaluated in phase 2 clinial trials for the treatment of primary sclerosing cholangitis & suspected moderate to severe liver fibrosis.
Lead Product(s): Bexotegrast
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: PLN-74809
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 04, 2024
Details:
PLN-74809 (bexotegrast), is an oral small molecule dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC.
Lead Product(s): Bexotegrast
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: PLN-74809
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2023
Details:
PLN-74809 (bexotegrast), is an oral small molecule dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC.
Lead Product(s): Bexotegrast
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: PLN-74809
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 09, 2023
Details:
PLN-74809 (bexotegrast), is an oral small molecule dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis and primary sclerosing cholangitis.
Lead Product(s): Bexotegrast
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: PLN-74809
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 30, 2023
Details:
PLN-74809 (bexotegrast), is an oral small molecule dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC.
Lead Product(s): Bexotegrast
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: PLN-74809
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 13, 2023
Details:
Pliant intends to use the net proceeds to develop its ongoing and future preclinical and clinical programs including PLN-74809 (bexotegrast) and PLN-101095, further develop its integrin targeting platform, to fund working capital and for other general corporate purposes.
Lead Product(s): Bexotegrast
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: PLN-74809
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $287.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 27, 2023
Details:
Pliant intends to use the net proceeds to develop its ongoing and future preclinical and clinical programs including PLN-74809 (bexotegrast) and PLN-101095, further develop its integrin targeting platform, to fund working capital and for other general corporate purposes.
Lead Product(s): Bexotegrast
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: PLN-74809
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $250.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 24, 2023
Details:
PLN-74809 (bexotegrast), is an oral small molecule dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC.
Lead Product(s): Bexotegrast
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: PLN-74809
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2023
Details:
PLN-74809 (bexotegrast), is an oral small molecule dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC.
Lead Product(s): Bexotegrast
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: PLN-74809
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2022
Details:
PLN-74809 (bexotegrast), is an oral, small molecule, dual-selective inhibitor of αvβ6 and αvβ1 being developed for the treatment of IPF and primary sclerosing cholangitis (PSC).
Lead Product(s): Bexotegrast
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: PLN-74809
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 01, 2022
Details:
PLN-74809 (bexotegrast), is an oral small molecule dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis (IPF), and primary sclerosing cholangitis (PSC).
Lead Product(s): Bexotegrast
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: PLN-74809
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2022
Details:
Pliant intends to use the proceeds from the offering, to develop its ongoing and future preclinical and clinical programs including PLN-74809 (bexotegrast), further develop its integrin targeting platform, to fund working capital, operating expenses and capital expenditures.
Lead Product(s): Bexotegrast
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: PLN-74809
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $230.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 15, 2022
Details:
Pliant intends to use the net proceeds from the offering, together with its existing cash, cash equivalents and investments, to develop its ongoing and future preclinical and clinical programs including PLN-74809, further develop its integrin targeting platform.
Lead Product(s): Bexotegrast
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: PLN-74809
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $200.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 12, 2022
Details:
Pliant intends to use the proceeds from the proposed offering, to develop its ongoing and future preclinical and clinical programs including PLN-74809 (bexotegrast), further develop its integrin targeting platform, to fund working capital, and for general corporate purposes.
Lead Product(s): Bexotegrast
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: PLN-74809
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 11, 2022
Details:
The trial met both primary and secondary endpoints demonstrating that PLN-74809 (bexotegrast) was well tolerated over a 12-week treatment period and displayed a favorable pharmacokinetic profile.
Lead Product(s): Bexotegrast
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: PLN-74809
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 10, 2022
Details:
In precision-cut liver slices, PLN-74809, an oral dual αvß6 / αvß1 integrin inhibitor reduced TGF-β-driven COL1A1 and COL1A2 gene expression in a dose-dependent manner.
Lead Product(s): Bexotegrast
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: PLN-74809
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2022
Details:
Poster summarizes findings from preclinical studies investigating antifibrotic activity resulting from dual αvß6 and αvß1 integrin inhibition by PLN-74809 in precision-cut liver slices from patients with PSC and in vivo models of PSC.
Lead Product(s): Bexotegrast
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: PLN-74809
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2022
Details:
Results from this Phase 1b proof-of-mechanism trial in healthy subjects showed that PLN-74809 inhibited TGF-β activation, a key mediator of the fibrosis pathway, in a sustained, dose dependent manner in the lungs of healthy participants.
Lead Product(s): Bexotegrast
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: PLN-74809
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2022
Details:
This facility will support the continued clinical development of PLN-74809, an oral, small molecule, dual selective inhibitor of αvß6 and αvß1 integrins, in the lead indications of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC).
Lead Product(s): Bexotegrast
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: PLN-74809
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Oxford Finance
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 05, 2022
Details:
PLN-74809, is an oral small molecule dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC.
Lead Product(s): Bexotegrast
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: PLN-74809
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2022
Details:
The completion of enrollment of INTEGRIS-IPF and the FDA authorization of long-term dosing of PLN-74809 in idiopathic pulmonary fibrosis with top-line data expected in mid-2022.
Lead Product(s): Bexotegrast
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: PLN-74809
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 11, 2022
Details:
Single dose administration of PLN-74809 achieved αvβ6 target engagement up to 98% in the lungs of IPF patients. PLN-74809 reached highly fibrotic regions of the lung and was bound to αvβ6 in IPF patients.
Lead Product(s): Bexotegrast
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: PLN-74809
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2021
Details:
Pliant Therapeutics' lead candidate, PLN-74809, is being developed for the treatment of idiopathic pulmonary fibrosis, and the company is currently recruiting for two Phase 2a clinical trials.
Lead Product(s): Bexotegrast
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cities
Deal Size: $86.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 11, 2020
Details:
Pliant plans to use the proceeds from the financing to support the continued clinical development of PLN-74809 in idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC).
Lead Product(s): Bexotegrast
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing March 03, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
